In the past week, OBIO stock has gone up by 4.36%, with a monthly gain of 2.87% and a quarterly plunge of -49.02%. The volatility ratio for the week is 11.47%, and the volatility levels for the last 30 days are 13.70% for Orchestra BioMed Holdings Inc The simple moving average for the past 20 days is 4.88% for OBIO’s stock, with a -43.52% simple moving average for the past 200 days.
Is It Worth Investing in Orchestra BioMed Holdings Inc (NASDAQ: OBIO) Right Now?
Additionally, the 36-month beta value for OBIO is 0.66. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OBIO is 26.64M and currently, short sellers hold a 2.03% ratio of that float. The average trading volume of OBIO on May 09, 2025 was 347.43K shares.
OBIO) stock’s latest price update
Orchestra BioMed Holdings Inc (NASDAQ: OBIO)’s stock price has gone rise by 16.67 in comparison to its previous close of 2.46, however, the company has experienced a 4.36% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that NEW HOPE, Pa., May 07, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced continued expansion of its global intellectual property (IP) estate supporting its proprietary AVIM therapy pipeline (formerly known as Cardiac Neuromodulation Therapy or “CNT”). Over the past 12 months, the Company has secured 10 new patents related to treatment of hypertension. The Company has also secured a total of 17 patents covering application of the technology for treatment of heart failure, significantly expanding the reach of its IP platform.
Analysts’ Opinion of OBIO
Many brokerage firms have already submitted their reports for OBIO stocks, with BTIG Research repeating the rating for OBIO by listing it as a “Buy.” The predicted price for OBIO in the upcoming period, according to BTIG Research is $12 based on the research report published on March 20, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see OBIO reach a price target of $16. The rating they have provided for OBIO stocks is “Overweight” according to the report published on January 02nd, 2025.
H.C. Wainwright gave a rating of “Buy” to OBIO, setting the target price at $14 in the report published on August 22nd of the previous year.
OBIO Trading at -17.59% from the 50-Day Moving Average
After a stumble in the market that brought OBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.64% of loss for the given period.
Volatility was left at 13.70%, however, over the last 30 days, the volatility rate increased by 11.47%, as shares sank -2.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.33% lower at present.
During the last 5 trading sessions, OBIO rose by +4.36%, which changed the moving average for the period of 200-days by -64.04% in comparison to the 20-day moving average, which settled at $2.74. In addition, Orchestra BioMed Holdings Inc saw -28.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OBIO starting from RTW INVESTMENTS, LP, who purchase 49,900 shares at the price of $2.99 back on Apr 30 ’25. After this action, RTW INVESTMENTS, LP now owns 8,306,063 shares of Orchestra BioMed Holdings Inc, valued at $149,201 using the latest closing price.
RTW INVESTMENTS, LP, the 10% Owner of Orchestra BioMed Holdings Inc, purchase 50,000 shares at $2.53 during a trade that took place back on Apr 29 ’25, which means that RTW INVESTMENTS, LP is holding 8,256,163 shares at $126,500 based on the most recent closing price.
Stock Fundamentals for OBIO
Current profitability levels for the company are sitting at:
- -24.37 for the present operating margin
- 0.89 for the gross margin
The net margin for Orchestra BioMed Holdings Inc stands at -23.13. The total capital return value is set at -1.07. Equity return is now at value -120.84, with -71.21 for asset returns.
Based on Orchestra BioMed Holdings Inc (OBIO), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -3.06.
Currently, EBITDA for the company is -64.3 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 39.51. The receivables turnover for the company is 28.67for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.27.
Conclusion
In conclusion, Orchestra BioMed Holdings Inc (OBIO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
